Ibrutinib Dose Reduction - An ASH Abstract - CLL Support

CLL Support

22,987 members39,473 posts

Ibrutinib Dose Reduction - An ASH Abstract

gardening-girl profile image
3 Replies

In yesterday's discussion about the effect of ibrutinib on hair-texture, the topic of ibrutinib dose reduction was mentioned ( healthunlocked.com/cllsuppo... ). There is an ASH abstract reporting very encouraging results from a pilot study assessing ibrutinib dose reduction:

Abstract 4307 A Pilot Study of Lower Doses of Ibrutinib in Patients (pts) with Chronic Lymphocytic Leukemia

CLL

Conclusions: Taken together, these data suggest that IBR doses as low as 140 mg/d are sufficient to fully occupy BTK and abrogate kinase function. As off-target effects of IBR are not thought to contribute to clinical efficacy in CLL, exploration of lower doses is warranted to reduce the incidence of troublesome side effects such as AF and bleeding, while preserving efficacy. Accordingly, a larger, more definitive trial with clinical endpoints of IBR at a dose of 140 mg/d following 2 cycles at 420 and 280 mg/d is planned.

ash.confex.com/ash/2017/web...

Written by
gardening-girl profile image
gardening-girl
To view profiles and participate in discussions please or .
Read more about...
3 Replies
PlanetaryKim profile image
PlanetaryKim

Great news! Thanks for sharing.

starsafta profile image
starsafta

I've been waiting to hear results of this study. So glad to see it. With lowered platelets and increased bleeding issues, I'm really hoping dose reduction can become standard. When I asked at my appointment at Dana Farber a few weeks ago, I was told they are not deviating from full strength at this time. I will offer myself as a guinea pig should they decide to run their own study. My numbers look great except for platelets. Seems worth trying, at least to me.

Thanks, Chris, for all your trolling and sharing.

Indolent profile image
Indolent

Yes, this will be a topic worthy of further study. The one-size-fits-all dosing seems counter intuitive. Yet even the experts in this field are still adhering to the "gospel" of the 420 mg dosing.

Not what you're looking for?

You may also like...

MUST READ for those on Ibrutinib/Imbruvica - concerning advice in pilot study on lower dosing - incl. danger of starting with a lower dose

I'm repeating in full, this very important advice posted by Dr Rick Furman in the CLL/SLL Groups.io...

Updated Results: Combined Ibrutinib and Venetoclax for 1st lineTreatment for CLL

Michael J Keating et al Dec 2019 - ASH oral presentation Here they report updated data for the 80...

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease.

December 8, 2019 ASH poster. There are lots of us on long term Ibrutinib who have had a good...

ASH 2018: ECOG trial shows superiority of Ibrutinib and rituximab over FCR

Hi friends, The early buzz at ASH 2018 was rightly about the ECOG trial that was presented on the...

ASH 2018: Professor Peter Hillmen on the Combination of Ibrutinib and Obinutuzumab in CLL: Timing Matters

Today we start with an important abstract from the United Kingdom that may have significant...